Posting of Annual Report & Notice of AGM
May 22, 2023 16:15 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company...
The FDA (Food and Drug Administration) Drug Approval Process Training Course: A Practical Insight into FDA Requirements
May 22, 2023 04:28 ET
|
Research and Markets
Dublin, May 22, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
May 18, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the...
Kallelse till extra bolagsstämma i Infant Bacterial Therapeutics
May 16, 2023 17:31 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), org.nr 556873-8586, med säte i Stockholm, kallar till extra bolagsstämma fredagen den 9 juni 2023 kl. 10.00 i bolagets lokaler på Bryggargatan 10, Stockholm. ...
Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics
May 16, 2023 17:31 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting to be held on Friday June 9, 2023 at 10.00...
IBT beslutar om en företrädesemisson
May 16, 2023 17:00 ET
|
Infant Bacterial Therapeutics AB
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SCHWEIZ, SINGAPORE, SYDAFRIKA,...
IBT resolves on a rights issue
May 16, 2023 17:00 ET
|
Infant Bacterial Therapeutics AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND,...
Årsstämma i Infant Bacterial Therapeutics
May 08, 2023 11:25 ET
|
Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 8 maj 2023 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen samt koncernresultaträkningen och...
Annual General Meeting of Infant Bacterial Therapeutics
May 08, 2023 11:25 ET
|
Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2023, among other things, the following was resolved: to adopt the income statement and balance sheet and the...
Infant Bacterial Therapeutics AB (publ), Interim report January 1-March 31, 2023
May 08, 2023 07:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO Significant advancements have been made in the development of microbiome-based pharmaceuticals in the past few months. Ferring/Rebiotics' product REBYOTA™ was approved by the...